The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The quinolones: decades of development and use
Open accessAbstract
The discovery of nalidixic acid in 1962, and its introduction for clinical use in 1967, marks the beginning of five decades of quinolone development and use. It was not until the discovery and licensing of the fluoroquinolones in the 1970s and 1980s that these drugs began to establish their place in the armamentarium of clinically useful antimicrobials. At the beginning of the 21st century, in their fifth decade of discovery and use, our understanding of structure-function relationships has improved, and better compounds, in terms of both spectrum of antimicrobial cover and pharmacokinetics, have been developed. The clinical utility of this expanding class of antimicrobial agents, and the lower propensity for the development of resistance with the "newer" fluoroquinolones will need to be continually monitored in the changing therapeutic environment. Antibiotic drug choice will remain difficult in the presence of increasing resistance, but the introduction of the new fluoroquinolones has created a new and exciting era in antimicrobial treatment. The role of these agents has already been acknowledged in a number of clinical guidelines, and appropriate use of these agents may help to preserve their clinical utility, enabling them to realize their full therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Gellert, M., Mizuuchi, K., O'Dea, M. H., & Nash, H. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3872 · Cited by 1,204
Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., & Tomizawa, J.-I. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4772 · Cited by 833
1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962) · Journal of Medicinal and Pharmaceutical Chemistry · doi:10.1021/jm01240a021 · Cited by 766
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Domagala, J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.4.685 · Cited by 681
The fluoroquinolone antibacterials: past, present and future perspectives
Appelbaum, P. C., & Hunter, P. A. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00192-8 · Cited by 629
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
(2001) · PubMed · doi:10.1136/thorax.56.suppl_4.iv1 · Cited by 272
Resistance among Streptococcus pneumoniae:Implications for Drug Selection
Appelbaum, P. C. (2002) · Clinical Infectious Diseases · doi:10.1086/340400 · Cited by 260
Comparative Tolerability of the Newer Fluoroquinolone Antibacterials
Ball, P., Mandell, L., Niki, Y., & Tillotson, G. (1999) · Drug Safety · doi:10.2165/00002018-199921050-00005 · Cited by 228
Cited by
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
Collin, F., Karkare, S., & Maxwell, A. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3557-z · Cited by 606
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents
Khan, T., Sankhe, K., Suvarna, V., Sherje, A., Patel, K., & Dravyakar, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.021 · Cited by 253
Metadata
- Authors
- Emmerson, A. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05-01
- Volume
- 51
- Issue
- 90001
- Pages
- 13-20
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2133193437
- Cited by
- 531
- References
- 30
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The quinolones: decades of development and use. https://app.cochat.ai/papers/10.1093/jac/dkg208
- The paper
- Emmerson, A. M. (2003). The quinolones: decades of development and use. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkg208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
